India is moving closer to a major breakthrough against dengue, with an indigenous vaccine candidate already undergoing advanced clinical testing. The ICMR and Panacea Biotec’s DengiAll, a tetravalent vaccine designed to target all four dengue virus types, entered Phase III trials involving more than 10,000 volunteers across India.
The development could bring a new tool against a disease that affects thousands of Indians every year, particularly during the monsoon season. However, the indigenous vaccine still needs to complete the required evaluation and regulatory process before wider rollout.
India has also taken another major step: in July 2026, regulators approved Qdenga, making it the country's first dengue vaccine authorised for prevention.
With both domestic research and international vaccine options advancing, India could see a significant change in its dengue-prevention strategy in the coming years.
The development could bring a new tool against a disease that affects thousands of Indians every year, particularly during the monsoon season. However, the indigenous vaccine still needs to complete the required evaluation and regulatory process before wider rollout.
India has also taken another major step: in July 2026, regulators approved Qdenga, making it the country's first dengue vaccine authorised for prevention.
With both domestic research and international vaccine options advancing, India could see a significant change in its dengue-prevention strategy in the coming years.